Silk Road MedicalNASDAQ: SILK

MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $27.50 per share in cash for which Silk Road Medical, Inc. (Nasdaq: SILK) (“SILK”) has agreed to be sold to Boston Scientific Corporation (“Boston Scientific”).

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silk Road Medical, Inc. (NasdaqGS: SILK) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Silk Road will receive $27.50 in cash for each share of Silk Road that they own. KSF is seeking to determine whether this consideration and the process that led to.

Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NEW YORK , June 18, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Silk Road Medical, Inc. (NASDAQ: SILK) and its board of directors concerning the proposed acquisition of the company by Boston Scientific Corporation (NYSE: BSX). Stockholders will receive $27.50 for each share of Silk Road Medical stock that they hold.

MILWAUKEE , June 18, 2024 /PRNewswire/ -- Ademi LLP is investigating Silk Road Medical (Nasdaq: SILK) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific. Click here to learn how to join the https://www.ademilaw.com/case/silk-road-medical-inc or call Guri Ademi toll-free at 866-264-3995.

SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a leading shareholder rights law firm, announced today that it has initiated an investigation into the board members of Silk Road Medical, Inc. (NASDAQ: SILK) concerning potential breaches of fiduciary duties related to the proposed sale of the Company to Boston Scientific (NYSE:BSX).

Silk Road Medical, Inc. (Nasdaq: SILK) will release its financial results for the first quarter of 2024 after the market closes on April 30th, 2024. A live audio webcast hosted by company management will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.

Silk Road Medical (SILK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.